{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T02:09:08Z","timestamp":1785809348314,"version":"3.56.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":243,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.ctarc.2025.100993","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T06:42:48Z","timestamp":1756795368000},"page":"100993","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Clinical and molecular characteristics of 42 Danish patients with metastatic ALK fusion-positive lung cancer treated with first-line alectinib: A nationwide study"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6482-8139","authenticated-orcid":false,"given":"Maiken Parm","family":"Ulh\u00f8i","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma Roger","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoffer Trier","family":"Maansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Munch","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslaw","family":"Stelmach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon Lykkegaard","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin Holmskov","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tine","family":"McCulloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Sorensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Meldgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ctarc.2025.100993_bib0001","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The Effect of Advances in Lung-Cancer Treatment on Population Mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ctarc.2025.100993_bib0002","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2025.100993_bib0003","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.ctarc.2025.100993_bib0004","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ctarc.2025.100993_bib0005","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41568-019-0179-8","article-title":"Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy","volume":"19","author":"Skoulidis","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ctarc.2025.100993_bib0006","unstructured":"\"Danish Lung Cancer Register Annual Report 2024\", 2025 https:\/\/www.lungecancer.dk\/rapporter\/aarsrapporter\/. Accessed June 28, 2025."},{"issue":"6","key":"10.1016\/j.ctarc.2025.100993_bib0007","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s11523-023-01014-z","article-title":"Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study)","volume":"18","author":"Dhamelincourt","year":"2023","journal-title":"Target. Oncol."},{"issue":"21","key":"10.1016\/j.ctarc.2025.100993_bib0008","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"7153","key":"10.1016\/j.ctarc.2025.100993_bib0009","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.ctarc.2025.100993_bib0010","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1634\/theoncologist.2016-0488","article-title":"ALK Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy","volume":"22","author":"Ross","year":"2017","journal-title":"Oncologist"},{"issue":"25","key":"10.1016\/j.ctarc.2025.100993_bib0011","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.ctarc.2025.100993_bib0012","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2025.100993_bib0013","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S2213-2600(22)00437-4","article-title":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet. Respir. Med."},{"key":"10.1016\/j.ctarc.2025.100993_bib0014","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.lungcan.2017.12.004","article-title":"ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer","volume":"116","author":"McLeer-Florin","year":"2018","journal-title":"Lung Cancer."},{"issue":"7","key":"10.1016\/j.ctarc.2025.100993_bib0015","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/annonc\/mdr535","article-title":"Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma","volume":"23","author":"Hofman","year":"2012","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2025.100993_bib0016","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/JTO.0b013e31827db604","article-title":"Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas","volume":"8","author":"Sholl","year":"2013","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2025.100993_bib0017","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jtho.2017.11.117","article-title":"Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: results from the European Thoracic Oncology Platform Lungscape Project","volume":"13","author":"Letovanec","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2025.100993_bib0018","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40487-021-00144-6","article-title":"When Tissue is an Issue the Liquid Biopsy is Nonissue: a Review","volume":"9","author":"Rodriguez","year":"2021","journal-title":"Oncol. Ther."},{"issue":"10","key":"10.1016\/j.ctarc.2025.100993_bib0019","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","article-title":"Liquid Biopsy for Advanced NSCLC: a Consensus Statement From the International Association for the Study of Lung Cancer","volume":"16","author":"Rolfo","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2025.100993_bib0020","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.18632\/oncotarget.13741","article-title":"Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer","volume":"8","author":"Cui","year":"2017","journal-title":"Oncotarget"},{"issue":"15","key":"10.1016\/j.ctarc.2025.100993_bib0021","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1002\/cam4.4663","article-title":"Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors","volume":"11","author":"Kwon","year":"2022","journal-title":"Cancer Med."},{"issue":"15","key":"10.1016\/j.ctarc.2025.100993_bib0022","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1158\/1078-0432.CCR-19-0624","article-title":"Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer","volume":"25","author":"Leighl","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2025.100993_bib0023","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.lungcan.2021.06.012","article-title":"Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC","volume":"158","author":"Zhang","year":"2021","journal-title":"Lung Cancer."},{"issue":"12","key":"10.1016\/j.ctarc.2025.100993_bib0024","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1200\/JCO.2017.76.2294","article-title":"Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer","volume":"36","author":"Lin","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2025.100993_bib0025","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/1878-0261.13446","article-title":"EML4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries","volume":"17","author":"Elshatlawy","year":"2023","journal-title":"Mol. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2025.100993_bib0026","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/annonc\/mdw693","article-title":"Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer","volume":"28","author":"Woo","year":"2017","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.ctarc.2025.100993_bib0027","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1093\/annonc\/mdy333","article-title":"Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer","volume":"29","author":"Kron","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2025.100993_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101471","article-title":"Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations","volume":"23","author":"Canale","year":"2022","journal-title":"Transl. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2025.100993_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100333","article-title":"Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer","volume":"7","author":"Wolf","year":"2022","journal-title":"ESMO Open."},{"issue":"9","key":"10.1016\/j.ctarc.2025.100993_bib0030","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.ctarc.2025.100993_bib0031","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: final Results of Phase 3 ALTA-1L Trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"12","key":"10.1016\/j.ctarc.2025.100993_bib0032","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.jtho.2023.08.010","article-title":"Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: results of Phase 3 ALTA-3 Trial","volume":"18","author":"Yang","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"24","key":"10.1016\/j.ctarc.2025.100993_bib0033","doi-asserted-by":"crossref","first-page":"6212","DOI":"10.1158\/1078-0432.CCR-18-0386","article-title":"Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab","volume":"24","author":"Raja","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.ctarc.2025.100993_bib0034","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.jtho.2023.05.021","article-title":"Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC","volume":"18","author":"Soo","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2025.100993_bib0035","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2025.100993_bib0036","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12859-023-05259-3","article-title":"DNAfusion: an R\/Bioconductor package for increased sensitivity of detecting gene fusions in liquid biopsies","volume":"24","author":"Maansson","year":"2023","journal-title":"BMC Bioinform."},{"key":"10.1016\/j.ctarc.2025.100993_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2024.07.009","article-title":"Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: real-World Outcomes From the GuardantINFORM database","author":"Parikh","year":"2024","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.ctarc.2025.100993_bib0038","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/1759-7714.12834","article-title":"Alectinib treatment response in lung adenocarcinoma patient with novel EML4-ALK variant","volume":"9","author":"Song","year":"2018","journal-title":"Thorac. Cancer"},{"issue":"9","key":"10.1016\/j.ctarc.2025.100993_bib0039","article-title":"Alectinib Versus Crizotinib in Asian Patients With Treatment-Naive Advanced ALK-Positive NSCLC: five-Year Update From the Phase 3 ALESIA Study","volume":"5","author":"Zhou","year":"2024","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.ctarc.2025.100993_bib0040","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study","author":"Solomon","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.ctarc.2025.100993_bib0041","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1158\/0008-5472.CAN-23-2551","article-title":"Oncogene-Driven Non-Small Cell Lung Cancers in Patients with a History of Smoking Lack Smoking-Induced Mutations","volume":"84","author":"Huang","year":"2024","journal-title":"Cancer Res."},{"issue":"21","key":"10.1016\/j.ctarc.2025.100993_bib0042","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.ctarc.2025.100993_bib0043","article-title":"Real-World Treatment and Outcomes in ALK-Rearranged NSCLC: results From a Large U.S.-Based Database","volume":"5","author":"Chazan","year":"2024","journal-title":"JTO Clin. Res. Rep."},{"issue":"6","key":"10.1016\/j.ctarc.2025.100993_bib0044","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/his.13148","article-title":"The prevalence of ALK rearrangement in pulmonary adenocarcinomas in an unselected Caucasian population from a defined catchment area: impact of smoking","volume":"70","author":"Skov","year":"2017","journal-title":"Histopathology"},{"key":"10.1016\/j.ctarc.2025.100993_bib0045","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1200\/PO.20.00046","article-title":"Clonal Hematopoiesis in Late-Stage Non-Small-Cell Lung Cancer and Its Impact on Targeted Panel Next-Generation Sequencing","volume":"4","author":"Yaung","year":"2020","journal-title":"JCO Precis Oncol."},{"issue":"11","key":"10.1016\/j.ctarc.2025.100993_bib0046","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jtho.2023.07.023","article-title":"Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations","volume":"18","author":"Bearz","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ctarc.2025.100993_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2023.05.021","article-title":"Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC","author":"Soo","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2025.100993_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100527","article-title":"Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naive Japanese patients with ALK-positive non-small-cell lung cancer","volume":"7","author":"Hotta","year":"2022","journal-title":"ESMO Open."},{"issue":"5","key":"10.1016\/j.ctarc.2025.100993_bib0049","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/annonc\/mdz060","article-title":"Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer","volume":"30","author":"Blumenthal","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2025.100993_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107919","article-title":"Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer","volume":"195","author":"Bauman","year":"2024","journal-title":"Lung Cancer."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225001297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225001297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:35:21Z","timestamp":1765485321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294225001297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":50,"alternative-id":["S2468294225001297"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.100993","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and molecular characteristics of 42 Danish patients with metastatic ALK fusion-positive lung cancer treated with first-line alectinib: A nationwide study","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.100993","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100993"}}